Results 41 to 50 of about 72,581 (277)

An evidence-based algorithm for the utility of FDG-PET for diagnosing Alzheimer's disease according to presence of medial temporal lobe atrophy [PDF]

, 2015
BackgroundImaging biomarkers for Alzheimer's disease include medial temporal lobe atrophy (MTLA) depicted on computed tomography (CT) or magnetic resonance imaging (MRI) and patterns of reduced metabolism on fluorodeoxyglucose positron emission ...
Cam Donaldson, Christopher Davison, David Williams, Fahn, Jim Lloyd, John T. O'Brien, Karl Herholz, Kirsty Olsen, Michael J. Firbank, Nicky Barnett, Robert Barber, Roth, Schmidt, Sean J. Colloby   +13 more
core   +1 more source

Neuropsychiatric Symptoms Mimicking Dementia in a Patient Treated With Imatinib

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Tyrosine kinase inhibitors are the cornerstone of chronic myeloid leukemia treatment. Newer agents have more potency and a broader spectrum of action, but also a higher potential for neuropsychiatric side effects. We present a case of a patient on imatinib who developed progressive cognitive, mood, and behavioral alterations.
Ashley Jones, Samuele Bonomi, Keith E. Stockerl‐Goldstein, Randall J. Bateman   +3 more
wiley   +1 more source

Parkinson’s Disease and Dementia with Lewy Bodies: One and the Same

Journal of Parkinson’s Disease
The question whether Parkinson’s disease dementia (PDD) and dementia with Lewy bodies (DLB) are expressions of the same underlying disease has been vigorously debated for decades.
Per Borghammer, Niels Okkels, Daniel Weintraub   +2 more
doaj   +1 more source

Environmental risk factors provoke new thinking for prevention and treatment of dementia with Lewy bodies

Heliyon
In recent years, environmental factors have received attention in the pathogenesis of neurodegenerative diseases. Other than genetic factors, the identification of environmental factors and modifiable risk factors may create opportunities to delay the ...
Dinghao An, Yun Xu
doaj   +1 more source

Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials

Alzheimer’s Research & Therapy, 2020
Lewy body dementia (LBD), including dementia with Lewy bodies and Parkinson’s disease dementia, affects over a million people in the USA and has a substantial impact on patients, caregivers, and society.
Jennifer G. Goldman, Leah K. Forsberg, Bradley F. Boeve, Melissa J. Armstrong, David J. Irwin, Tanis J. Ferman, Doug Galasko, James E. Galvin, Daniel Kaufer, James Leverenz, Carol F. Lippa, Karen Marder, Victor Abler, Kevin Biglan, Michael Irizarry, Bill Keller, Leanne Munsie, Masaki Nakagawa, Angela Taylor, Todd Graham   +19 more
doaj   +1 more source

Interleukin-1 polymorphisms associated with increased risk of gastric cancer [PDF]

, 2000
Helicobacter pylori infection is associated with a variety of clinical outcomes including gastric cancer and duodenal ulcer disease. The reasons for this variation are not clear, but the gastric physiological response is influenced by the severity and ...
A Cox, B Ruiz, CA Dinarello, Charles S. Rabkin, Chiu-Chin Yuan, Correa, P., CR Yu, D Basso, DM Parkin, E El-Omar, E El-Omar, EJ Kuipers, EM El-Omar, Emad M. El-Omar, F Pociot, George Lanyon, HC Jung, Howard A. Young, HW Chow, IL Beales, Jay H. Bream, Jesus Herrera, JL Wallace, Jolanta Lissowska, Joseph F. Fraumeni, Kenneth E. L. McColl, LA Noach, LE Hansson, M Carrington, Mary Carrington, Maureen Martin, MJ Blaser, MM Wolfe, NA Tountas, Nathaniel Rothman, P Sipponen, RM Royall, RW Stockbruegger, S Santtila, T Andus, VA Danis, Wong-Ho Chow, Y Yamaoka   +42 more
core   +2 more sources

Clinical biomarkers for Lewy body diseases

Cell & Bioscience, 2023
AbstractSynucleinopathies are a group of neurodegenerative disorders characterized by pathologic aggregates of neural and glial α-synuclein (α-syn) in the form of Lewy bodies (LBs), Lewy neurites, and cytoplasmic inclusions in both neurons and glia. Two major classes of synucleinopathies are LB disease and multiple system atrophy.
Mai M. Abdelmoaty, Eugene Lu, Rana Kadry, Emma G. Foster, Shaurav Bhattarai, R. Lee Mosley, Howard E. Gendelman   +6 more
openaire   +3 more sources

Five‐Year Disease Progression in Synuclein Seeding Positive Sporadic Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To provide a comprehensive description of disease progression in synuclein seeding assay (SAA) positive sporadic Parkinson Disease participants, using Neuronal Synuclein Disease integrated biological and functional impairment staging framework.
Paulina Gonzalez‐Latapi, Caroline Gochanour, Seung Ho Choi, Hyunkeun Cho, Chelsea Caspell‐Garcia, Christopher Coffey, Michael Brumm, David‐Erick Lafontant, Yuge Xiao, Thomas Tropea, John Seibyl, Caroline Tanner, Charles S. Venuto, Karl Kieburtz, Lana M. Chahine, Kathleen L. Poston, Andrew Siderowf, Kenneth Marek, Tanya Simuni, The Parkinson's Progression Markers Initiative   +19 more
wiley   +1 more source

Value of MRI Outcomes for Preventive and Early‐Stage Trials in Spinocerebellar Ataxias 1 and 3

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To examine the value of MRI outcomes as endpoints for preventive and early‐stage trials of two polyglutamine spinocerebellar ataxias (SCAs). Methods A cohort of 100 participants (23 SCA1, 63 SCA3, median Scale for the Assessment and Rating of Ataxia (SARA) score = 5, 42% preataxic, and 14 gene‐negative controls) was scanned at 3T up ...
Thiago J. R. Rezende, Emilien Petit, Young Woo Park, Sophie Tezenas du Montcel, James M. Joers, Jonathan M. DuBois, H. Moore Arnold, Michal Povazan, Ipek Özdemir, Guita Banan, Romain Valabregue, Philipp Ehses, Jennifer Faber, Chiadi U. Onyike, Peter B. Barker, Jeremy D. Schmahmann, Eva‐Maria Ratai, Sub H. Subramony, Thomas H. Mareci, Khalaf O. Bushara, Henry Paulson, Thomas Klockgether, Alexandra Durr, Tetsuo Ashizawa, Christophe Lenglet, Gülin Öz, READISCA Investigators   +26 more
wiley   +1 more source

Baseline Regional Cholinergic Denervation Predicts Cognitive Trajectories in Moderate Parkinson Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Cognitive decline is a disabling and variable feature of Parkinson disease (PD). While cholinergic system degeneration is linked to cognitive impairments in PD, most prior research reported cross‐sectional associations. We aimed to fill this gap by investigating whether baseline regional cerebral vesicular acetylcholine transporter ...
Taylor Brown, Giulia Carli, Prabesh Kanel, Stiven Roytman, Jaimie Barr, Nicolaas I. Bohnen, Roger L. Albin   +6 more
wiley   +1 more source